Drug Profile

Research programme: vascular disease therapeutics - TI Pharma

Latest Information Update: 27 Jun 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Actelion Pharmaceuticals; Erasmus MC; Maastricht University; TI Pharma
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
16 Jul 2016 No recent reports of development identified for research development in Vascular-disorders in Netherlands
17 Nov 2009 Early research in Vascular disorders in Netherlands (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com